Living With a Disease That Attacks From the Inside
Imagine waking up in the middle of the night with pain so intense you can't move. Your bones ache. Your chest is tight. You don't know how long it will last — hours, sometimes days. For people with sickle cell disease, these episodes — called vaso-occlusive crises — are a defining part of life.
Sickle cell disease is caused by a mutation in the hemoglobin gene — hemoglobin being the protein in red blood cells that carries oxygen. That mutation causes red blood cells to take on a rigid, crescent shape. Those misshapen cells jam up blood vessels, cutting off oxygen and triggering devastating pain crises.
Current treatments help manage symptoms, but most don't address the root cause. That may be changing.
The Body Has a Hidden Backup
Here's something remarkable: when we're born, our bodies make a different kind of hemoglobin — fetal hemoglobin. It carries oxygen well. And it doesn't sickle.
Shortly after birth, a gene called BCL11A acts like an off switch, telling the body to stop making fetal hemoglobin and start making adult hemoglobin instead. In people with sickle cell disease, that switch is the problem.
Scientists asked: what if we could disable that off switch permanently?
Molecular Scissors, One-Time Treatment
A therapy called reni-cel uses CRISPR-Cas12a — a precise gene-editing tool often described as "molecular scissors" — to snip and disable the DNA sites that BCL11A uses to shut off fetal hemoglobin production.
Think of it like cutting the wires to the off switch. Once cut, the body stays in "fetal mode," making the safer, non-sickling version of hemoglobin.
The process: doctors collect a patient's own stem cells, edit them in a lab, and infuse them back into the patient. It's a one-time procedure. The patient's own edited cells do the work from that point forward.
What the Study Looked At
A phase 1-2 clinical trial published in The New England Journal of Medicine tested this approach in 28 patients with severe sickle cell disease. Participants were 12 to 50 years old and had experienced at least two severe crises per year in the two years before the study. They were followed for up to 25 months after infusion.
The Results Were Hard to Ignore
27 of 28 patients had zero vaso-occlusive crises after receiving the treatment.
That's a striking outcome in a disease where painful crises are the norm. Only one patient experienced two crises after infusion.
The biology backed it up. At six months, patients' total hemoglobin levels rose from an average of 9.8 g/dL to 13.8 g/dL — near normal range. Fetal hemoglobin climbed from 2.5% to 48.1%. Both numbers held steady over time. Side effects were consistent with what's expected after the conditioning chemotherapy required before any stem cell transplant.
But There's a Catch
This treatment is not available outside of a clinical trial.
The study was stopped early — not because of safety concerns, but because the company that sponsored it decided to shift its business priorities. That kind of decision happens in drug development, and it's a reminder that promising science doesn't always move in a straight line.
Where This Fits
This research adds to growing evidence that reactivating fetal hemoglobin is a real strategy for sickle cell disease. A related CRISPR therapy called Casgevy received FDA approval in 2023 — the first CRISPR treatment ever approved — using a similar but different approach. Reni-cel targets slightly different DNA sites using the Cas12a variant of CRISPR.
These early results suggest gene editing could transform sickle cell from a condition defined by crises into something managed with a single treatment.
What This Means for You Right Now
This research is worth knowing about — but it's not a treatment you can access today. Reni-cel's trial was terminated early, and its path to approval is uncertain.
The right step is to talk with your hematologist about what clinical trials may be available and whether gene therapy is worth exploring for your situation.
This study was small — 28 patients — and follow-up was relatively short, with a median of under 10 months. There was no control group, which makes it harder to rule out other explanations for the improvements. Most critically, the trial was cut short by the sponsor, limiting what we can say about long-term safety and durability. Larger trials would be needed to confirm these findings.
The early termination of this trial is a setback for reni-cel, but it doesn't slow the broader field. Multiple gene therapies for sickle cell disease are in development or regulatory review. The bigger challenge is access — gene therapies require specialized centers and currently cost millions of dollars, putting them out of reach for most patients worldwide. The science is moving. Getting it to the people who need it most is the next mountain to climb.
If a one-time gene therapy could free you from sickle cell crises, would the risks of the procedure feel worth it to you?
- Living with sickle cell disease: what patients need to know
- How CRISPR gene editing works in plain language
- FDA-approved sickle cell treatments: what's available now
